Avita Medical (ASX:AVH) launched wound care treatment Cohealyx in the US, according to a Friday filing with the Australian bourse.
Cohealyx is a collagen-based dermal matrix branded by Avita Medical and co-developed with Regenity Biosciences, the filing stated. It is designed to provide wound bed through cellular migration and revascularization for faster closure.
Avita Medical is enrolling participants in the Cohealyx I post-market trial.
The company's shares were down almost 4% in recent Friday trade.